|
medical sciences |
37 |
|
hepatocellular carcinoma |
33 |
|
chronic hepatitis b |
31 |
|
hepatitis b |
30 |
|
liver transplantation |
30 |
|
gastroenterology |
29 |
|
cirrhosis |
25 |
|
entecavir |
24 |
|
adult |
22 |
|
nafld |
22 |
|
antiviral therapy |
19 |
|
hbsag |
19 |
|
hepatitis b surface antigen |
19 |
|
hepatitis b virus |
19 |
|
hbv |
18 |
|
antiviral |
17 |
|
functional cure |
17 |
|
liver transplant |
17 |
|
nucleoside analogues |
16 |
|
adolescent |
15 |
|
aged |
15 |
|
disease severity |
15 |
|
female |
15 |
|
gastroenterology medical sciences |
15 |
|
humans |
15 |
|
male |
15 |
|
middle aged |
15 |
|
surgery |
15 |
|
cap |
14 |
|
flare |
14 |
|
liver fibrosis |
14 |
|
outcomes |
14 |
|
prognosis |
14 |
|
aged, 80 and over |
13 |
|
liver biopsy |
13 |
|
liver failure |
13 |
|
liver stiffness |
13 |
|
metabolic syndrome |
13 |
|
nucleos(t)ide analogue |
13 |
|
tenofovir |
13 |
|
vcte |
13 |
|
chronic viral hepatitis |
12 |
|
dna, viral - blood |
12 |
|
prediction |
12 |
|
risk factors |
12 |
|
acute flare |
11 |
|
age |
11 |
|
alanine aminotransferase |
11 |
|
anti-hbs |
11 |
|
antiviral agents - adverse effects - therapeutic use |
11 |
|
biomarkers |
11 |
|
cancer survival |
11 |
|
controlled attenuation parameter |
11 |
|
decompensation |
11 |
|
high-intensity focused ultrasound |
11 |
|
hong kong - epidemiology |
11 |
|
liver cirrhosis - complications - diagnosis |
11 |
|
living donor liver transplant |
11 |
|
longitudinal studies |
11 |
|
meld |
11 |
|
predictive value of tests |
11 |
|
prevention |
11 |
|
virus replication |
11 |
|
ablation |
10 |
|
alanine transaminase - blood |
10 |
|
biomarker |
10 |
|
bridging therapy |
10 |
|
genotype |
10 |
|
hepatitis b virus - genetics |
10 |
|
kidney transplantation |
10 |
|
m2bpgi |
10 |
|
models, biological |
10 |
|
mutation |
10 |
|
new technology |
10 |
|
survival |
10 |
|
treatment outcome |
10 |
|
11c-acetate |
9 |
|
adefovir |
9 |
|
age factors |
9 |
|
antiviral agents - therapeutic use |
9 |
|
asian continental ancestry group - statistics & numerical data |
9 |
|
carcinoma, hepatocellular - ethnology - pathology - virology |
9 |
|
carcinoma, hepatocellular - virology |
9 |
|
child |
9 |
|
child, preschool |
9 |
|
contrast ct |
9 |
|
fatty liver disease |
9 |
|
finite |
9 |
|
follow-up studies |
9 |
|
hbeag |
9 |
|
hepatitis b core-related antigen |
9 |
|
hepatitis b, chronic - pathology |
9 |
|
hepatitis c |
9 |
|
hepatocellular carcinoma (hcc) |
9 |
|
infant |
9 |
|
lamivudine |
9 |
|
liver |
9 |
|
liver - pathology - virology |
9 |
|
liver neoplasms - virology |
9 |
|
living donor liver transplantation |
9 |
|
milan criteria |
9 |
|
nash |
9 |
|
non-viral liver disease |
9 |
|
pet/ct |
9 |
|
pre-s deletions |
9 |
|
recurrence |
9 |
|
transarterial chemoembolization |
9 |
|
transient elastography |
9 |
|
tumorigenesis |
9 |
|
blood transfusion |
8 |
|
cadaver donor |
8 |
|
cancer invasion |
8 |
|
carcinoma, hepatocellular - surgery - virology |
8 |
|
cardiac function |
8 |
|
carrier state |
8 |
|
disease progression |
8 |
|
drug therapy, combination |
8 |
|
elasticity imaging techniques |
8 |
|
elasticity imaging techniques - methods |
8 |
|
endocrinology |
8 |
|
fibroscan |
8 |
|
fibrosis |
8 |
|
guanine - adverse effects - analogs and derivatives - therapeutic use |
8 |
|
hepatitis b, chronic - complications - diagnosis |
8 |
|
hepatitis b, chronic - complications - diagnosis - drug therapy - surgery |
8 |
|
hepatitis b, chronic - drug therapy - virology |
8 |
|
hla‐dp |
8 |
|
ifn‐γ pathway |
8 |
|
liver cirrhosis - pathology - virology |
8 |
|
liver cirrhosis - surgery - virology |
8 |
|
liver disease |
8 |
|
liver failure - pathology - virology |
8 |
|
longitudinal |
8 |
|
mortality |
8 |
|
natural history |
8 |
|
nephrotoxicity |
8 |
|
reproducibility of results |
8 |
|
seroconversion (sc) |
8 |
|
vaccination |
8 |
|
viral hepatitis |
8 |
|
waiting list |
8 |
|
abdominal abscess |
7 |
|
abdominal bleeding |
7 |
|
accuracy |
7 |
|
advanced cirrhosis |
7 |
|
alanine aminotransferase blood level |
7 |
|
alanine transaminase - metabolism |
7 |
|
body mass index |
7 |
|
cancer staging |
7 |
|
carcinoma, hepatocellular - etiology |
7 |
|
covalently closed circular dna |
7 |
|
de novo hbv |
7 |
|
de novo hepatocellular carcinoma |
7 |
|
deceased donor liver transplantation |
7 |
|
diagnostic test accuracy study |
7 |
|
dna, viral - analysis |
7 |
|
domino liver transplant |
7 |
|
drug response |
7 |
|
elastography |
7 |
|
epidemiology |
7 |
|
etv |
7 |
|
experience |
7 |
|
extended criteria organ |
7 |
|
graft-to-recipient weight ratio |
7 |
|
hbv dna |
7 |
|
hepatitis b e antigens - metabolism |
7 |
|
hepatitis b infection |
7 |
|
hepatitis b vaccination |
7 |
|
hepatitis b virus - physiology |
7 |
|
hepatitis b virus infection |
7 |
|
hepatitis b, chronic - blood - drug therapy - virology |
7 |
|
hepatitis b, chronic - complications |
7 |
|
hepatitis b, chronic - enzymology - pathology |
7 |
|
hepatorenal syndrome |
7 |
|
interferons |
7 |
|
itraq |
7 |
|
liver cirrhosis - enzymology - pathology |
7 |
|
liver cirrhosis - etiology |
7 |
|
living donor |
7 |
|
long-term survival |
7 |
|
mafld |
7 |
|
metabolic |
7 |
|
model for end-stage liver disease |
7 |
|
nucleoside analogue |
7 |
|
obesity |
7 |
|
prevalence |
7 |
|
primary biliary cirrhosis |
7 |
|
protein precursors - genetics |
7 |
|
retransplantation |
7 |
|
review |
7 |
|
right liver graft |
7 |
|
right-lobe |
7 |
|
small-for-size syndrome |
7 |
|
surface antigen |
7 |
|
survival outcomes |
7 |
|
transthyretin |
7 |
|
val30ala |
7 |
|
viral load |
7 |
|
young adult |
7 |
|
anti-hbc |
6 |
|
antibody to hepatitis b surface antigen |
6 |
|
aspartate aminotransferase |
6 |
|
bile leak |
6 |
|
biliary anastomotic stricture |
6 |
|
biliary complications |
6 |
|
biliary reconstruction |
6 |
|
blood donors - statistics and numerical data |
6 |
|
carcinoma, hepatocellular - diagnosis - epidemiology |
6 |
|
carcinoma, hepatocellular - etiology - pathology - surgery - virology |
6 |
|
carrier state - epidemiology - pathology |
6 |
|
cholangiograms |
6 |
|
chronic hepatitis b virus |
6 |
|
cigarette smoking |
6 |
|
circular dna |
6 |
|
deceased-donor liver transplantation |
6 |
|
drug resistance, viral |
6 |
|
ductal anomaly |
6 |
|
end-stage liver disease |
6 |
|
endoscopic retrograde cholangiography |
6 |
|
enhancer elements (genetics) - genetics |
6 |
|
fatty liver |
6 |
|
full-length genome sequencing |
6 |
|
genotype 1 |
6 |
|
genotype 6 |
6 |
|
gitr |
6 |
|
graft survival |
6 |
|
graft-weight-to-recipient-weight ratio |
6 |
|
guanine - analogs and derivatives - therapeutic use |
6 |
|
hepacivirus - classification - genetics - pathogenicity |
6 |
|
hepaticolenticular degeneration |
6 |
|
hepatitis b - complications |
6 |
|
hepatitis b antibodies - blood |
6 |
|
hepatitis b core‐related antigen |
6 |
|
hepatitis b e antigens - blood |
6 |
|
hepatitis b serum markers |
6 |
|
hepatitis b surface antigens - immunology |
6 |
|
hepatitis b virus - drug effects |
6 |
|
hepatitis b virus - genetics - immunology - isolation & purification |
6 |
|
hepatitis b virus - isolation and purification |
6 |
|
hepatitis b(e) antigen |
6 |
|
hepatitis b, chronic - blood - complications - genetics |
6 |
|
hepatitis b, chronic - complications - drug therapy |
6 |
|
hepatitis b, chronic - epidemiology - pathology |
6 |
|
hepatitis b, chronic - ethnology - immunology - pathology |
6 |
|
hepatitis c, chronic - complications - metabolism - virology |
6 |
|
hepatocellullar carconoma |
6 |
|
hepatocholangiocarcinoma |
6 |
|
host-pathogen interactions |
6 |
|
hs-hbsag |
6 |
|
immune exhaustion |
6 |
|
interleukin‐27 |
6 |
|
intrahepatic cholangiocarcinoma |
6 |
|
intrahepatic hbv dna |
6 |
|
keywords |
6 |
|
kinetics |
6 |
|
lamivudine - adverse effects - therapeutic use |
6 |
|
lamivudine - pharmacology - therapeutic use |
6 |
|
lamivudine - therapeutic use |
6 |
|
liver - pathology |
6 |
|
liver cirrhosis - ethnology - pathology - virology |
6 |
|
liver neoplasms - diagnosis - epidemiology |
6 |
|
liver neoplasms - ethnology - pathology - virology |
6 |
|
liver neoplasms - etiology |
6 |
|
liver neoplasms - etiology - pathology - surgery - virology |
6 |
|
liver resection |
6 |
|
liver resection (lr) |
6 |
|
liver transplantation (lt) |
6 |
|
living-donor liver transplantation |
6 |
|
mac-2 binding protein glycosylation isomer |
6 |
|
mass screening - methods |
6 |
|
mutation - genetics |
6 |
|
nomogram |
6 |
|
pd-1 |
6 |
|
pediatric donor |
6 |
|
platelet ratio index |
6 |
|
portal vein |
6 |
|
post-transplant recurrence |
6 |
|
predictive model |
6 |
|
primary biliary cholangitis |
6 |
|
primary transplantation |
6 |
|
promoter regions (genetics) - genetics |
6 |
|
propensity score matching |
6 |
|
proportional hazards models |
6 |
|
prospective studies |
6 |
|
quasispecies |
6 |
|
regulatory t cells |
6 |
|
resection |
6 |
|
resistance |
6 |
|
response to therapy |
6 |
|
reverse transcriptase inhibitors - therapeutic use |
6 |
|
right liver donation |
6 |
|
risk factor |
6 |
|
salvage transplantation |
6 |
|
seroepidemiologic studies |
6 |
|
sex factors |
6 |
|
small-for-size grafts |
6 |
|
spontaneous hbeag seroconversion |
6 |
|
survival analysis |
6 |
|
t regulatory cells |
6 |
|
telbivudine |
6 |
|
tenofovir hbsag surface antigen nucleoside analogue nucleotide analogue tdf |
6 |
|
time factors |
6 |
|
transplantation |
6 |
|
tumour thrombus |
6 |
|
ursodeoxycholic acid |
6 |
|
viral core proteins - genetics |
6 |
|
viral integration |
6 |
|
virus dna |
6 |
|
alkaline phosphatase - blood |
5 |
|
alpha-fetoprotein (afp) |
5 |
|
alpha-fetoproteins - analysis |
5 |
|
amoxicillin - pharmacology - therapeutic use |
5 |
|
anaemia |
5 |
|
anti-bacterial agents - pharmacology - therapeutic use |
5 |
|
antiviral agents - administration and dosage - therapeutic use |
5 |
|
aspartate aminotransferases - blood |
5 |
|
bilirubin - blood |
5 |
|
breath tests |
5 |
|
carcinoma, hepatocellular - diagnosis - pathology |
5 |
|
carcinoma, hepatocellular - epidemiology - genetics - virology |
5 |
|
china |
5 |
|
ddpcr |
5 |
|
deceased-donor liver re-transplantation |
5 |
|
deep sequencing |
5 |
|
dna, circular - analysis - isolation & purification |
5 |
|
dna, viral - analysis - isolation & purification |
5 |
|
dna-directed dna polymerase - genetics |
5 |
|
drugs, chinese herbal - adverse effects |
5 |
|
fibrosis regression |
5 |
|
freezing |
5 |
|
gamma-glutamyltransferase - blood |
5 |
|
gene deletion |
5 |
|
gene expression regulation, viral |
5 |
|
globulins - analysis |
5 |
|
graft failure |
5 |
|
guanine - administration and dosage - analogs and derivatives - therapeutic use |
5 |
|
hbeag seroconversion |
5 |
|
hbsag seroclearance |
5 |
|
hbv // chb |
5 |
|
helicobacter infections - drug therapy - metabolism |
5 |
|
helicobacter pylori |
5 |
|
hepacivirus - genetics |
5 |
|
hepatic artery thrombosis |
5 |
|
hepatitis b core antigens - genetics |
5 |
|
hepatitis b surface antigens - blood |
5 |
|
hepatitis b surface antigens - blood - chemistry |
5 |
|
hepatitis b surface antigens - genetics |
5 |
|
hepatitis b surface antigens - metabolism |
5 |
|
hepatitis b virus - chemistry - classification - genetics |
5 |
|
hepatitis b virus - classification - genetics |
5 |
|
hepatitis b virus - drug effects - enzymology - genetics |
5 |
|
hepatitis b virus - drug effects - genetics |
5 |
|
hepatitis b virus - genetics - immunology - isolation and purification |
5 |
|
hepatitis b virus - genetics - isolation and purification |
5 |
|
hepatitis b virus dna rebound |
5 |
|
hepatitis b virus replication |
5 |
|
hepatitis b, chronic - blood - drug therapy |
5 |
|
hepatitis b, chronic - complications - genetics - virology |
5 |
|
hepatitis b, chronic - complications - mortality - pathology |
5 |
|
hepatitis b, chronic - complications - virology |
5 |
|
hepatitis b, chronic - drug therapy |
5 |
|
hepatitis b, chronic - drug therapy - enzymology - immunology |
5 |
|
hepatitis b, chronic - epidemiology - physiopathology - virology |
5 |
|
hepatitis c virus |
5 |
|
hepatitis c, chronic - drug therapy - virology |
5 |
|
immunomodulator |
5 |
|
interferon-alpha - therapeutic use |
5 |
|
intrahepatic hepatitis b virus dna |
5 |
|
lamivudine - administration & dosage - therapeutic use |
5 |
|
liver - metabolism |
5 |
|
liver - virology |
5 |
|
liver biochemistry |
5 |
|
liver cirrhosis |
5 |
|
liver cirrhosis - diagnosis |
5 |
|
liver diseases - etiology |
5 |
|
liver histology |
5 |
|
liver neoplasms - epidemiology - genetics - virology |
5 |
|
living-donor liver re-transplantation |
5 |
|
medicine, chinese traditional - adverse effects |
5 |
|
nucleosides - pharmacology - therapeutic use |
5 |
|
occult hepatitis b infection |
5 |
|
ofloxacin - pharmacology - therapeutic use |
5 |
|
omeprazole - pharmacology - therapeutic use |
5 |
|
pcr |
5 |
|
polyethylene glycols - therapeutic use |
5 |
|
polymorphism, genetic |
5 |
|
promoter regions, genetic - genetics |
5 |
|
protein stability |
5 |
|
pyrimidinones - pharmacology - therapeutic use |
5 |
|
qpcr |
5 |
|
quantitative |
5 |
|
recombinant proteins |
5 |
|
reverse transcriptase inhibitors - administration & dosage - therapeutic use |
5 |
|
reverse transcriptase polymerase chain reaction |
5 |
|
ribavirin |
5 |
|
ribavirin - therapeutic use |
5 |
|
rna, messenger - analysis - isolation & purification |
5 |
|
rna, viral - analysis - isolation & purification |
5 |
|
roc curve |
5 |
|
s-loss |
5 |
|
seroclearance |
5 |
|
single polynucleotide polymorphisms |
5 |
|
specimen handling - methods |
5 |
|
statins |
5 |
|
statistics, nonparametric |
5 |
|
stopping |
5 |
|
sustained virologic response |
5 |
|
therapeutic vaccine |
5 |
|
treatment guidelines |
5 |
|
tumor |
5 |
|
viral suppression |
5 |
|
week 12 |
5 |
|
week 24 |
5 |
|
acute-on-chronic liver failure |
4 |
|
adenine - analogs & derivatives - therapeutic use |
4 |
|
adjuvant |
4 |
|
age distribution |
4 |
|
alt |
4 |
|
antibody-mediated rejection |
4 |
|
antisense oligonucleotide |
4 |
|
antiviral agents |
4 |
|
antiviral agents - pharmacology - therapeutic use |
4 |
|
antiviral treatment |
4 |
|
asian continental ancestry group |
4 |
|
asian continental ancestry group - ethnology |
4 |
|
aso |
4 |
|
blood - virology |
4 |
|
blood transfusion - adverse effects |
4 |
|
capsid inhibitor |
4 |
|
carcinoma, hepatocellular - diagnosis - virology |
4 |
|
case-control studies |
4 |
|
cccdna |
4 |
|
china - ethnology |
4 |
|
cohort studies |
4 |
|
combination |
4 |
|
core protein allosteric modulator |
4 |
|
cure |
4 |
|
deceased donor liver transplant |
4 |
|
dna, circular - analysis |
4 |
|
dna, viral - genetics - isolation and purification |
4 |
|
dose-response relationship, immunologic |
4 |
|
drug resistance, multiple, viral - genetics |
4 |
|
drug resistance, viral - genetics |
4 |
|
efficacy |
4 |
|
elasticity |
4 |
|
entry inhibitor |
4 |
|
enzyme-linked immunosorbent assay - methods |
4 |
|
genome editing |
4 |
|
global elimination |
4 |
|
guanine - analogs & derivatives - therapeutic use |
4 |
|
hbcrag |
4 |
|
hbsag level |
4 |
|
hbv infection |
4 |
|
hbv rna |
4 |
|
hcc |
4 |
|
hepatitis |
4 |
|
hepatitis b - immunology - prevention & control |
4 |
|
hepatitis b - transmission |
4 |
|
hepatitis b antibodies - blood - immunology |
4 |
|
hepatitis b core antigen |
4 |
|
hepatitis b core antigens - blood |
4 |
|
hepatitis b e antigen (hbeag) |
4 |
|
hepatitis b immune globulin |
4 |
|
hepatitis b vaccines - administration & dosage - immunology |
4 |
|
hepatitis b virus (hbv) dna |
4 |
|
hepatitis b virus - chemistry |
4 |
|
hepatitis b virus - classification - genetics - isolation and purification |
4 |
|
hepatitis b virus rna |
4 |
|
hepatitis b, chronic - blood - drug therapy - genetics |
4 |
|
hepatitis b, chronic - blood - drug therapy - immunology |
4 |
|
hepatitis b, chronic - complications - drug therapy - ethnology |
4 |
|
hepatitis b, chronic - diagnosis |
4 |
|
hepatitis b, chronic - etiology |
4 |
|
hong kong |
4 |
|
hq-hbsag |
4 |
|
ici |
4 |
|
immune checkpoint inhibitors |
4 |
|
immunization schedule |
4 |
|
immunization, secondary |
4 |
|
immunogenicity |
4 |
|
immunologic memory |
4 |
|
immunomodulators |
4 |
|
integrated dna |
4 |
|
lamivudine - administration & dosage |
4 |
|
left lobe graft |
4 |
|
liver cirrhosis - diagnosis - epidemiology - virology |
4 |
|
liver cirrhosis - pathology |
4 |
|
liver neoplasms - diagnosis - virology |
4 |
|
long-term |
4 |
|
luminescent measurements - methods |
4 |
|
necrosis - pathology |
4 |
|
neoadjuvant |
4 |
|
noninvasive |
4 |
|
novel therapy |
4 |
|
nucleoside analog |
4 |
|
nucleotide analog |
4 |
|
oral therapy |
4 |
|
phosphonic acids - therapeutic use |
4 |
|
pneumocystis jirovecii |
4 |
|
pneumocystis pneumonia |
4 |
|
polymerase inhibitor |
4 |
|
post-liver transplant |
4 |
|
programmed cell death protein 1 |
4 |
|
real-life |
4 |
|
retrospective studies |
4 |
|
reverse transcriptase inhibitors - administration & dosage |
4 |
|
right lobe graft |
4 |
|
rna interfering gene silencer |
4 |
|
rnai |
4 |
|
serology |
4 |
|
sex distribution |
4 |
|
sirna |
4 |
|
small for size liver graft |
4 |
|
statistics as topic |
4 |
|
systemic therapy |
4 |
|
t cells |
4 |
|
tki |
4 |
|
tlr7 agonist |
4 |
|
transplants |
4 |
|
vaccine |
4 |
|
vaccines, dna - administration & dosage - immunology |
4 |
|
viral entry inhibitor |
4 |
|
viremia |
4 |
|
adoptive immunity transfer |
3 |
|
age of onset |
3 |
|
alcoholic liver disease |
3 |
|
alemtuzumab |
3 |
|
anti-ulcer agents - therapeutic use |
3 |
|
antiviral agents - administration & dosage - adverse effects - pharmacokinetics - therapeutic use |
3 |
|
antiviral agents - administration and dosage |
3 |
|
belatacept |
3 |
|
biological markers |
3 |
|
calcineurin inhibitor |
3 |
|
carcinogenesis |
3 |
|
carcinoma, hepatocellular - epidemiology - virology |
3 |
|
chi-square distribution |
3 |
|
chronic disease |
3 |
|
chronic hepatitis b therapy |
3 |
|
chronic hepatitis c infection |
3 |
|
chronic kidney disease |
3 |
|
chronic viral infection |
3 |
|
corticosteroid |
3 |
|
creatine kinase |
3 |
|
creatine kinase - blood |
3 |
|
cyclosporine |
3 |
|
dialysis |
3 |
|
direct-acting antiviral |
3 |
|
direct-acting antivirals |
3 |
|
double-blind method |
3 |
|
drug monitoring |
3 |
|
drug resistance |
3 |
|
erectile dysfunction |
3 |
|
esophagitis - drug therapy - ethnology |
3 |
|
esophagoscopy |
3 |
|
etiology |
3 |
|
everolimus |
3 |
|
gastric acidity determination |
3 |
|
gastro-oesophageal reflux disease |
3 |
|
guanine - adverse effects - analogs & derivatives - pharmacology - therapeutic use |
3 |
|
hbv vaccination |
3 |
|
hepacivirus - pathogenicity |
3 |
|
hepatitis b surface antigens - blood - immunology |
3 |
|
hepatitis b treatment |
3 |
|
hepatitis b virus - drug effects - genetics - isolation & purification |
3 |
|
hepatitis b virus - pathogenicity |
3 |
|
hepatitis b, chronic - complications - epidemiology |
3 |
|
hepatitis b, chronic - diagnosis - drug therapy |
3 |
|
hepatitis b, chronic - diagnosis - drug therapy - immunology - virology |
3 |
|
hepatitis b, chronic - epidemiology |
3 |
|
hepatitis c, chronic - epidemiology |
3 |
|
hydrogen-ion concentration |
3 |
|
hypogonadism |
3 |
|
immunoglobulin |
3 |
|
immunologic factors - therapeutic use |
3 |
|
immunosuppression |
3 |
|
infection control |
3 |
|
isoenzymes - blood |
3 |
|
lamivudine - administration and dosage |
3 |
|
lb80380 |
3 |
|
liver cirrhosis, biliary - epidemiology |
3 |
|
liver diseases - epidemiology - etiology |
3 |
|
liver diseases, alcoholic - epidemiology |
3 |
|
logistic models |
3 |
|
manometry |
3 |
|
mtor inhibitor |
3 |
|
multicenter studies as topic - statistics & numerical data |
3 |
|
muscular diseases - blood - chemically induced |
3 |
|
mycophenolate |
3 |
|
myopathy |
3 |
|
nucleosides - administration & dosage - adverse effects - pharmacokinetics - therapeutic use |
3 |
|
nucleotide analogue |
3 |
|
oesophagitis |
3 |
|
omeprazole - therapeutic use |
3 |
|
pegylated interferon/ribavirin |
3 |
|
peripheral nervous system diseases - chemically induced |
3 |
|
ph monitoring |
3 |
|
phosphonic acids - adverse effects - pharmacology - therapeutic use |
3 |
|
practice guidelines as topic |
3 |
|
pregnancy |
3 |
|
pregnancy complications, infectious - drug therapy |
3 |
|
proton pump inhibitors |
3 |
|
pyrimidinones - administration & dosage - adverse effects - pharmacokinetics - therapeutic use |
3 |
|
questionnaires |
3 |
|
randomized controlled trials as topic |
3 |
|
safety |
3 |
|
severity of illness index |
3 |
|
sexual dysfunction |
3 |
|
sirolimus |
3 |
|
sotrastaurin |
3 |
|
steatosis |
3 |
|
sustained virological response |
3 |
|
tacrolimus |
3 |
|
tofacitinib |
3 |
|
treg |
3 |
|
viral proteins - physiology |
3 |
|
virulence factors - physiology |
3 |
|
voclosporin |
3 |
|
acute drug administration |
2 |
|
adverse outcome |
2 |
|
asia |
2 |
|
b12 deficiency |
2 |
|
bacterial clearance |
2 |
|
bacterial growth |
2 |
|
chb |
2 |
|
covid-19 |
2 |
|
diagnosis |
2 |
|
disease burden |
2 |
|
hcv |
2 |
|
historical |
2 |
|
incidence |
2 |
|
modelling |
2 |
|
outcome |
2 |
|
policy |
2 |
|
treatment |
2 |
|
benefit |
1 |
|
chronic hepatitis c |
1 |
|
congresses as topic |
1 |
|
direct acting antivirals |
1 |
|
disease outbreaks |
1 |
|
drug resistance, bacterial |
1 |
|
hepacivirus - drug effects |
1 |
|
hepatitis b, chronic - drug therapy - epidemiology - virology |
1 |
|
hepatitis c, chronic - drug therapy - epidemiology - virology |
1 |
|
influenza a virus, h1n1 subtype - drug effects |
1 |
|
influenza, human - epidemiology - prevention & control - virology |
1 |
|
unmet needs |
1 |
